Biocompatibility Under ISO 10993: A Risk-Based Approach to Biological Evaluation

Biocompatibility is the ability of a medical device to perform its intended function without causing unacceptable harm to the patient from its materials. Under ISO 10993-1, demonstrating it is not a matter of running a fixed list of laboratory tests. It is a structured, risk-based biological evaluation: you characterize the device and its materials, identify the biological risks that matter for how the device contacts the body, and then decide what evidence (existing data, chemical characterization, or new testing) is needed to address each risk. Regulators expect the rationale, not just the results.

Biocompatibility Is a Process, Not a Checklist

The most common misunderstanding is treating the endpoint tables in ISO 10993-1 as a menu of mandatory tests. They are a starting point for planning. The standard requires you to justify which endpoints apply, why existing information is sufficient, and where new data is needed. Two devices in the same contact category can end up with very different evaluation strategies because their materials, processing, and clinical use differ. The goal is a defensible conclusion about biological safety, supported by a clear line of reasoning.

Categorize the Device by Nature and Duration of Contact

Everything begins with categorization, because it determines which biological endpoints you must consider. ISO 10993-1 classifies devices along two axes:

• Nature of body contact. Surface devices (contacting intact skin, mucosal membranes, or breached surfaces), external communicating devices (contacting the blood path, tissue, bone, or dentin), and implant devices (contacting tissue, bone, or blood).
• Duration of contact. Limited (up to 24 hours), prolonged (24 hours to 30 days), and long-term (more than 30 days). Repeated or cumulative exposure is counted toward the longer category.

A device that contacts circulating blood for hours carries a very different risk profile than a skin-contact device, and a permanent implant carries more still. Getting the category right is the single most important early decision.

Consider the Full Set of Biological Endpoints

Once categorized, you evaluate the biological endpoints relevant to that category. The endpoints most often in scope include:

• Cytotoxicity. The baseline screen for nearly all devices, detecting cell damage from leachable substances.
• Sensitization and irritation. Delayed allergic response and local tissue reaction from materials and residues.
• Acute, subacute, and chronic systemic toxicity. Systemic effects scaled to the duration of exposure.
• Genotoxicity, carcinogenicity, and reproductive toxicity. Considered chiefly for prolonged and long-term contact.
• Implantation. Local tissue effects for implanted and tissue-contacting devices.
• Hemocompatibility. Interaction with blood for any blood-contacting device, covering thrombosis, coagulation, and hemolysis.
• Material-mediated pyrogenicity. Fever response attributable to the materials themselves.

The Shift Toward Chemical Characterization

Modern biological evaluation increasingly leads with chemistry rather than animals. ISO 10993-18 describes chemical characterization: identifying and quantifying the extractable and leachable substances a device can release. Those results feed a toxicological risk assessment (ISO 10993-17), where measured exposures are compared against tolerable intake levels to judge whether a chemical risk is acceptable. Done well, this approach can address several toxicological endpoints (systemic toxicity, genotoxicity, and more) without new animal studies, which aligns with the widely adopted principle of reducing, refining, and replacing animal testing. It also demands rigor: appropriate extraction conditions, validated analytical methods, and defensible analytical evaluation thresholds.

Document It in a BEP and a BER

The reasoning is captured in two living documents. The Biological Evaluation Plan (BEP) is written up front: it records the device categorization, the endpoints considered, the rationale for addressing or excluding each one, and the strategy (existing data, chemical characterization, or testing) for each. The Biological Evaluation Report (BER) gathers the executed evidence and states the overall conclusion on biological safety. Both should be authored by a competent evaluator and kept current as the design, materials, or manufacturing change. Reviewers read the BEP and BER first, so gaps in reasoning there undermine otherwise sound data.

Regulatory Expectations: FDA and EU MDR

In the United States, FDA recognizes ISO 10993-1 and issues its own guidance, "Use of International Standard ISO 10993-1," which sets FDA-specific expectations in premarket submissions, including additional endpoint attention and a preference for well-documented chemical characterization. In the European Union, the Medical Device Regulation (EU MDR 2017/745) requires biological safety to be demonstrated in the technical documentation, with the harmonized ISO 10993 series serving as the practical route to showing conformity with the relevant general safety and performance requirements. In both jurisdictions, the expectation is the same: a traceable, risk-based evaluation that a reviewer can follow from category to conclusion.

Common Pitfalls

• Testing the wrong sample. Evaluation must use finished, sterilized, representative product, not raw resin or an early prototype, because processing and sterilization change the chemistry.
• Ignoring manufacturing residuals. Mold-release agents, cleaning agents, adhesives, and sterilization byproducts are frequent sources of leachables and are easy to overlook.
• Missing endpoints or weak rationale. Skipping an applicable endpoint without justification, or excluding one with a rationale that does not hold up, is a leading cause of deficiency letters.
• Treating the file as static. A material change, a new supplier, or a sterilization change can invalidate prior conclusions and require re-evaluation.

How Sequence Group Can Help

Biological evaluation is where materials science, toxicology, and regulatory strategy meet, and small missteps are expensive to correct late. Sequence Group helps device manufacturers categorize contact correctly, build a defensible Biological Evaluation Plan, decide when chemical characterization can stand in for animal testing, and assemble a Biological Evaluation Report that holds up under FDA and EU MDR review. If you are planning a submission or revisiting an aging biocompatibility file, we can help you get the reasoning and the evidence aligned. Contact us to discuss your device.